Figure 3.

MCB-613, when given within hours post-MI, induces lasting protection from adverse remodeling concomitant with (1) inhibition of macrophage inflammatory signaling and IL-1 signaling which attenuates the acute inflammatory response, (2) prevention of fibroblast differentiation, and (3) promotion of Tsc22d3 expressing macrophages—all of which may limit inflammatory damage. SRC stimulation with MCB-613 is a potential novel therapeutic approach for inhibiting cardiac dysfunction after MI. LAD, left anterior descending artery; IP intraperitoneal.